Outcomes after chemotherapy with WHO category II regimen in a population with high prevalence of drug resistant tuberculosis.
Van der Stuyft, P
AffiliationEpidemiological and Disease Control Unit, Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium. firstname.lastname@example.org
MetadataShow full item record
AbstractStandard short course chemotherapy is recommended by the World Health Organization to control tuberculosis worldwide. However, in settings with high drug resistance, first line standard regimens are linked with high treatment failure. We evaluated treatment outcomes after standardized chemotherapy with the WHO recommended category II retreatment regimen in a prison with a high prevalence of drug resistant tuberculosis (TB). A cohort of 233 culture positive TB patients was followed through smear microscopy, culture, drug susceptibility testing and DNA fingerprinting at baseline, after 3 months and at the end of treatment. Overall 172 patients (74%) became culture negative, while 43 (18%) remained positive at the end of treatment. Among those 43 cases, 58% of failures were determined to be due to treatment with an inadequate drug regimen and 42% to either an initial mixed infection or re-infection while under treatment. Overall, drug resistance amplification during treatment occurred in 3.4% of the patient cohort. This study demonstrates that treatment failure is linked to initial drug resistance, that amplification of drug resistance occurs, and that mixed infection and re-infection during standard treatment contribute to treatment failure in confined settings with high prevalence of drug resistance.
- Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases.
- Authors: Tabarsi P, Chitsaz E, Tabatabaei V, Baghaei P, Shamaei M, Farnia P, Marjani M, Kazempour M, Mansouri D, Masjedi MR, Velayati AA
- Issue date: 2011 Sep
- Association between Regimen Composition and Treatment Response in Patients with Multidrug-Resistant Tuberculosis: A Prospective Cohort Study.
- Authors: Yuen CM, Kurbatova EV, Tupasi T, Caoili JC, Van Der Walt M, Kvasnovsky C, Yagui M, Bayona J, Contreras C, Leimane V, Ershova J, Via LE, Kim H, Akksilp S, Kazennyy BY, Volchenkov GV, Jou R, Kliiman K, Demikhova OV, Vasilyeva IA, Dalton T, Cegielski JP
- Issue date: 2015 Dec
- Bacterial risk factors for treatment failure and relapse among patients with isoniazid resistant tuberculosis.
- Authors: Thai PVK, Ha DTM, Hanh NT, Day J, Dunstan S, Nhu NTQ, Kiet VS, Lan NH, Dung NH, Lan NTN, Thuong NT, Lan NN, Liễu PTT, Hồng NT, Điệp ĐC, Thanh NTK, Hội NV, Nghĩa NV, Đại TN, Minh HQ, Thơm NV, Farrar J, Caws M
- Issue date: 2018 Mar 6
- [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
- Authors: Saito W, Nagayama N, Miyamoto M, Hara H, Suzuki J, Masuda K, Baba M, Tamura A, Nagai H, Akagawa S, Kawabe Y, Machida K, Kurashima A, Yotsumoto H
- Issue date: 2003 Oct
- Tuberculosis and multidrug resistance in Zambian prisons, 2000-2001.
- Authors: Habeenzu C, Mitarai S, Lubasi D, Mudenda V, Kantenga T, Mwansa J, Maslow JN
- Issue date: 2007 Nov